Inclusion of Polypills for Prevention of Cardiovascular Disease in the 23rd World Health Organization Model List of Essential Medicines: A Significant Step Towards Reducing Global Cardiovascular Morbidity and Mortality
This commentary describes the potential impact of inclusion of polypills for prevention of cardiovascular disease in the 23rd WHO Model List of Essential Medicines, and provides a roadmap for adoption, implementation, sustainment, and scale-up. The World Health Organization's endorsement of pol...
Gespeichert in:
| Veröffentlicht in: | Global heart Jg. 19; H. 1; S. 24 |
|---|---|
| Hauptverfasser: | , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
England
Ubiquity Press
01.01.2024
|
| Schlagworte: | |
| ISSN: | 2211-8179, 2211-8179 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | This commentary describes the potential impact of inclusion of polypills for prevention of cardiovascular disease in the 23rd WHO Model List of Essential Medicines, and provides a roadmap for adoption, implementation, sustainment, and scale-up. The World Health Organization's endorsement of polypills is essential for improving global access, particularly in low- and middle-income countries. The greatest health gains are expected in a primary prevention population which has a significantly higher burden of fatal and non-fatal cardiovascular disease compared with the population of individuals with prevalent cardiovascular disease. A focus on adoption, implementation, sustainment, and scale-up of polypills for prevention of cardiovascular disease is needed including increasing supply of available polypills and incorporating polypills into the World Health Organization HEARTS technical package for integration into primary care systems to realize these benefits for population health. Widespread implementation of polypills for prevention of cardiovascular disease has the potential to equitably reduce the impact of cardiovascular disease globally by simplifying treatment options and expanding accessibility across economic levels, both across and within countries. |
|---|---|
| AbstractList | This commentary describes the potential impact of inclusion of polypills for prevention of cardiovascular disease in the 23rd WHO Model List of Essential Medicines, and provides a roadmap for adoption, implementation, sustainment, and scale-up. The World Health Organization’s endorsement of polypills is essential for improving global access, particularly in low- and middle-income countries. The greatest health gains are expected in a primary prevention population which has a significantly higher burden of fatal and non-fatal cardiovascular disease compared with the population of individuals with prevalent cardiovascular disease. A focus on adoption, implementation, sustainment, and scale-up of polypills for prevention of cardiovascular disease is needed including increasing supply of available polypills and incorporating polypills into the World Health Organization HEARTS technical package for integration into primary care systems to realize these benefits for population health. Widespread implementation of polypills for prevention of cardiovascular disease has the potential to equitably reduce the impact of cardiovascular disease globally by simplifying treatment options and expanding accessibility across economic levels, both across and within countries. This commentary describes the potential impact of inclusion of polypills for prevention of cardiovascular disease in the 23rd WHO Model List of Essential Medicines, and provides a roadmap for adoption, implementation, sustainment, and scale-up. The World Health Organization's endorsement of polypills is essential for improving global access, particularly in low- and middle-income countries. The greatest health gains are expected in a primary prevention population which has a significantly higher burden of fatal and non-fatal cardiovascular disease compared with the population of individuals with prevalent cardiovascular disease. A focus on adoption, implementation, sustainment, and scale-up of polypills for prevention of cardiovascular disease is needed including increasing supply of available polypills and incorporating polypills into the World Health Organization HEARTS technical package for integration into primary care systems to realize these benefits for population health. Widespread implementation of polypills for prevention of cardiovascular disease has the potential to equitably reduce the impact of cardiovascular disease globally by simplifying treatment options and expanding accessibility across economic levels, both across and within countries.This commentary describes the potential impact of inclusion of polypills for prevention of cardiovascular disease in the 23rd WHO Model List of Essential Medicines, and provides a roadmap for adoption, implementation, sustainment, and scale-up. The World Health Organization's endorsement of polypills is essential for improving global access, particularly in low- and middle-income countries. The greatest health gains are expected in a primary prevention population which has a significantly higher burden of fatal and non-fatal cardiovascular disease compared with the population of individuals with prevalent cardiovascular disease. A focus on adoption, implementation, sustainment, and scale-up of polypills for prevention of cardiovascular disease is needed including increasing supply of available polypills and incorporating polypills into the World Health Organization HEARTS technical package for integration into primary care systems to realize these benefits for population health. Widespread implementation of polypills for prevention of cardiovascular disease has the potential to equitably reduce the impact of cardiovascular disease globally by simplifying treatment options and expanding accessibility across economic levels, both across and within countries. |
| Author | Huffman, Mark D. Agarwal, Anubha |
| Author_xml | – sequence: 1 givenname: Anubha orcidid: 0000-0002-7090-5601 surname: Agarwal fullname: Agarwal, Anubha – sequence: 2 givenname: Mark D. orcidid: 0000-0001-7412-2519 surname: Huffman fullname: Huffman, Mark D. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38434154$$D View this record in MEDLINE/PubMed |
| BookMark | eNpdksFuEzEQQFeoiJZS8QfIN7ikrNfeOMutCqWNlKgVLeJozdqzG1eOndreovCpfA1OmiIUX-yx37yxNPO2OHLeYVG8p-V5zRj_3C_PKaPlq-KkqigdTahojv47HxdnMT6UedVj2vDqTXHMJpxxWvOT4s_MKTtE4x3xHbn1drM21kbS-UBuAz6hS_u3KQRt_BNENVgI5KuJCBGJcSQtkVQsaPLTB6vJNYJNS3ITenDmN-zyF16jJXMT01Z1GePWC5YsUBtlHMYv5ILcmd6ZzihwidwlXJN7_ysXjeQ76iFTPbmyvs1ZB19Z-NAabdKGgNPbKIHN0bvidQc24tl-Py1-fLu8n16P5jdXs-nFfKQ4F2nUloILEJ3iIARVgilBJzUgpxNskFdV3dFxK0RbI2dVp1sxhrJuMMPjcatadlrMnr3aw4NcB7OCsJEejNxd-NBLCMkoixJbNtFdUzWdqDg2umGlaoFXHWjWaM2z69Ozax3844AxyZWJCq0Fh36IsmqYyC3njGX0wx4d2hXqf4VfepuB0TOggo8xYCeVSbt2pADGSlrK7fjIfim345P5jwf8i_KQ_AsnRcfR |
| CitedBy_id | crossref_primary_10_1161_CIRCOUTCOMES_124_011121 crossref_primary_10_1016_j_ajpc_2025_101019 crossref_primary_10_1016_j_jocn_2025_111446 |
| Cites_doi | 10.1136/bmj.326.7404.1419 10.1056/NEJMoa1311890 10.1016/j.jacc.2022.12.003 10.1016/j.jacc.2017.11.056 10.1056/NEJMoa2208275 |
| ContentType | Journal Article |
| Copyright | Copyright: © 2024 The Author(s). |
| Copyright_xml | – notice: Copyright: © 2024 The Author(s). |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 DOA |
| DOI | 10.5334/gh.1310 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2211-8179 |
| EndPage | 24 |
| ExternalDocumentID | oai_doaj_org_article_eb38df929f724e9d930cba42fad39dd4 38434154 10_5334_gh_1310 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: K99 HL157687 |
| GroupedDBID | --- --M .0O .1- .FO .~1 0R~ 1~. 1~5 4.4 457 4G. 53G 7-5 8P~ AAEDT AAFWJ AAIKJ AAKOC AALRI AAOAW AAYXX ABBQC ABMZM ACCQO ACDAQ ACGFS ADBBV ADEZE AEKER AEVXI AFPKN AFRHN AFTJW AGHFR AGUBO AGYEJ AJRQY ALMA_UNASSIGNED_HOLDINGS ANZVX BLXMC CITATION FDB FIRID FNPLU GBLVA GROUPED_DOAJ H13 HX~ IAO INH ITC J1W MO0 O-L O9- OAUVE OK1 P-8 P-9 PC. PGMZT PQQKQ Q38 RPM SDF SEL SSZ W2D Z5R ~G- ~HD --K 5VS AAQFI AAXUO ABWVN ABXDB ACRPL ADMUD ADNMO AIGII AITUG AJUYK CGR CUY CVF EBS ECM EIF EJD HZ~ M41 NPM ROL 7X8 |
| ID | FETCH-LOGICAL-c447t-b0747a7fc4a771c73c7185ae418e9e4225f16b77b5e432fdb76a059e77166bcb3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 4 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001230185900019&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2211-8179 |
| IngestDate | Fri Oct 03 12:37:36 EDT 2025 Thu Oct 02 07:55:39 EDT 2025 Mon Jul 21 05:33:24 EDT 2025 Sat Nov 29 07:06:40 EST 2025 Tue Nov 18 22:35:38 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Cardiovascular disease World Health Organization essential medicines polypills |
| Language | English |
| License | Copyright: © 2024 The Author(s). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c447t-b0747a7fc4a771c73c7185ae418e9e4225f16b77b5e432fdb76a059e77166bcb3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-7090-5601 0000-0001-7412-2519 |
| OpenAccessLink | https://doaj.org/article/eb38df929f724e9d930cba42fad39dd4 |
| PMID | 38434154 |
| PQID | 2937334433 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_eb38df929f724e9d930cba42fad39dd4 proquest_miscellaneous_2937334433 pubmed_primary_38434154 crossref_citationtrail_10_5334_gh_1310 crossref_primary_10_5334_gh_1310 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-01-01 |
| PublicationDateYYYYMMDD | 2024-01-01 |
| PublicationDate_xml | – month: 01 year: 2024 text: 2024-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Global heart |
| PublicationTitleAlternate | Glob Heart |
| PublicationYear | 2024 |
| Publisher | Ubiquity Press |
| Publisher_xml | – name: Ubiquity Press |
| References | (key20240306000515_B4) 2022; 387 (key20240306000515_B5) 2020; 76 key20240306000515_B2 (key20240306000515_B7) 2018; 71 (key20240306000515_B1) 2003; 326 (key20240306000515_B6) 2014; 371 (key20240306000515_B3) 2023; 81 |
| References_xml | – volume: 326 start-page: 1419 year: 2003 ident: key20240306000515_B1 article-title: A strategy to reduce cardiovascular disease by more than 80% publication-title: BMJ doi: 10.1136/bmj.326.7404.1419 – volume: 371 start-page: 818 year: 2014 ident: key20240306000515_B6 article-title: Cardiovascular risk and events in 17 low-, middle-, and high-income countries publication-title: N Engl J Med doi: 10.1056/NEJMoa1311890 – volume: 76 start-page: 2982 year: 2020 ident: key20240306000515_B5 article-title: Global burden of cardiovascular diseases and risk factors, 1990–2019 update from the GBD 2019 study publication-title: J Am Coll Cardiol – volume: 81 start-page: 620 year: 2023 ident: key20240306000515_B3 article-title: Medication use for cardiovascular disease prevention in 40 low- and middle-income countries publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2022.12.003 – ident: key20240306000515_B2 – volume: 71 start-page: 564 year: 2018 ident: key20240306000515_B7 article-title: Modernizing the World Health Organization list of essential medicines for preventing and controlling cardiovascular diseases publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2017.11.056 – volume: 387 start-page: 967 year: 2022 ident: key20240306000515_B4 article-title: Polypill strategy in secondary cardiovascular prevention publication-title: N Engl J Med doi: 10.1056/NEJMoa2208275 |
| SSID | ssj0000561942 |
| Score | 2.3263023 |
| SecondaryResourceType | review_article |
| Snippet | This commentary describes the potential impact of inclusion of polypills for prevention of cardiovascular disease in the 23rd WHO Model List of Essential... |
| SourceID | doaj proquest pubmed crossref |
| SourceType | Open Website Aggregation Database Index Database Enrichment Source |
| StartPage | 24 |
| SubjectTerms | cardiovascular disease Cardiovascular Diseases - prevention & control essential medicines Humans polypills Population Health World Health Organization |
| Title | Inclusion of Polypills for Prevention of Cardiovascular Disease in the 23rd World Health Organization Model List of Essential Medicines: A Significant Step Towards Reducing Global Cardiovascular Morbidity and Mortality |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38434154 https://www.proquest.com/docview/2937334433 https://doaj.org/article/eb38df929f724e9d930cba42fad39dd4 |
| Volume | 19 |
| WOSCitedRecordID | wos001230185900019&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: Directory of Open Access Journals customDbUrl: eissn: 2211-8179 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000561942 issn: 2211-8179 databaseCode: DOA dateStart: 20200101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9RADB5BhRAXxLvLozIS4ha6m5nECbdSWnFoqwqKtLdonttIUVJtdpH4q_wa7Ex2tYAQF45JRplRbMefZ-zPQrxxaSA1MZhMlVSJQsRE5zIk6DRaPZU6c0PXkjO8uCjm8_Jyp9UX54RFeuD44Q4p2CtcICceMFW-dKWcWqNVGrSTpXMDEyihnp1gKrJ6c3SexipZrjY9XFy_m0muk91xPwNL_9-h5eBiTh-I-yM2hKO4pofilm8fibvn4-n3Y_GDjLlZ8_YWdAEuu-b7Td00PRDuhA0VU3x2_EuWKXyMpzBQt0B4D1K5dDBk0UCsQoLdikzg9mgNnJH8-VUnPZcnkZbCZiH9eziCL_Wi5SwjEgxwphhcDfm3PXxmLljyhxC7Cfy-lPNuaWpH0B906_hqNQQCT8TX05Or40_J2JshsUrhKjFMvK8xWKURZxalJSeXaa9mhS-9or9EmOUG0WReyTQ4g7kmJOdpcJ4ba-RTsdd2rd8XkOYBC1tmzDVH3jHTs7woNTKHqJXSlBPxdiOyyo7E5dw_o6kogGHZVovrimU7EbAdeBO5Ov4c8oFlvn3M5NrDDVK5alS56l8qNxGvNxpTkTHyCYtufbfuK8JOSLMpKSfiWVSl7VSyIGsgwPr8fyzhhbiXErqKe0Evxd5qufavxB37bVX3ywNxG-fFwWARPwHJpxR_ |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inclusion+of+Polypills+for+Prevention+of+Cardiovascular+Disease+in+the+23rd+World+Health+Organization+Model+List+of+Essential+Medicines%3A+A+Significant+Step+Towards+Reducing+Global+Cardiovascular+Morbidity+and+Mortality&rft.jtitle=Global+heart&rft.au=Anubha+Agarwal&rft.au=Mark+D.+Huffman&rft.date=2024-01-01&rft.pub=Ubiquity+Press&rft.eissn=2211-8179&rft.volume=19&rft.issue=1&rft.spage=24&rft.epage=24&rft_id=info:doi/10.5334%2Fgh.1310&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_eb38df929f724e9d930cba42fad39dd4 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2211-8179&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2211-8179&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2211-8179&client=summon |